Cerebrolysin
Not FDA approvedPorcine brain-derived peptide mixture
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 43 registered studies on ClinicalTrials.gov, most advanced Phase 4
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Cerebrolysin is a mixture of low molecular weight peptides and free amino acids derived from pig brain tissue. It is thought to act in ways similar to natural neurotrophic factors, possibly supporting nerve cell survival and repair, though its exact mechanism is not well defined.
What the evidence shows
It is not FDA-approved in the United States, though it has been studied in about 43 registered human trials, mainly in stroke, traumatic brain injury, and dementia. Results have been mixed, and systematic reviews have not established clear, consistent benefit.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion
Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke
Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain Injury
Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke.
Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke.
Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.